Key facts
- HeXembio’s last known valuation is $25.0M (Mar 2025).
- It has raised $19.8M.
- Notable investors include Alumni Ventures, SOSV, Gaingels, Draper Associates, IndieBio — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for HeXembio
- ·The full record, as it builds
Funding rounds
No funding rounds for HeXembio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HeXembio
Developer of a cell restoration technology designed to enable longevity. The company offers regenerative medicine approaches with scalable and reproducible stem cell therapies, enabling aging individuals to restore healthy hematopoietic stem cell function and reverse the effects of aging.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2024
- Employees
- 8
- Website
- hexemb.io/
- Ownership
- Privately Held (backing)
HeXembio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HeXembio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HeXembio in its N-PORT filings yet. We sweep new filings monthly.